Tapentadol differs from tramadol as an analgesic agent in that tapentadol:

• A Has both mu-opioid agonism and norepinephrine reuptake inhibition, with much weaker serotonin reuptake inhibitory effects than tramadol ✓
• B Is a prodrug requiring CYP2D6 conversion to an active opioid metabolite, making it CYP2D6 genotype dependent
• C Acts solely as a norepinephrine-dopamine reuptake inhibitor with no opioid receptor activity
• D Has pure mu-opioid agonism without any monoamine reuptake inhibition

Explanation

Both tapentadol and tramadol combine mu-opioid agonism with monoamine reuptake inhibition, but the balance differs importantly. Tapentadol has roughly equal contributions from mu-opioid agonism and norepinephrine reuptake inhibition (NRI) to its analgesia, with minimal serotonin reuptake inhibition — reducing the risk of serotonin syndrome and seizures seen with tramadol. Tramadol is a prodrug relying on CYP2D6 for conversion to O-desmethyltramadol (the potent opioid metabolite) — option B describes tramadol, NOT tapentadol. Tapentadol is not a prodrug and does not require CYP2D6 conversion.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.